DRMA · XBRL financial data

Dermata Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DRMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	903	1,135*	1,601	2,009	2,401	2,192*	1,281	618	504	527*	384	213
Selling, general and administrative	—	—	—	—	824	1,008*	1,059	1,155	1,256	1,374*	1,543	2,801
General and administrative	909	1,085*	1,603	875	824	1,008*	1,059	1,155	—	—	—	—
Total operating expenses	1,812	2,220*	3,204	2,884	3,226	3,200*	2,340	1,773	1,761	1,900*	1,926	3,014
Operating income (loss)	(1,812)	(2,220)*	(3,204)	(2,884)	(3,226)	(3,200)*	(2,340)	(1,773)	(1,761)	(1,900)*	(1,926)	(3,014)
Interest income	—	—	69	55	52	49*	36	72	69	39*	79	47
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	—	—	—
Net income (loss)	(1,719)	(2,134)*	(3,134)	(2,829)	(3,173)	(3,151)*	(2,304)	(1,701)	(1,692)	(1,862)*	(1,848)	(2,967)
Earnings per share, basic USD per share	(0.54)	—	(7.06)	(41.82)	(20.41)	—	(0.45)	(1.66)	(1.65)	—	(0.48)	(0.74)
Earnings per share, diluted USD per share	—	—	(7.06)	(41.82)	(20.41)	—	(0.45)	(1.66)	(1.65)	—	(0.48)	(0.74)
Weighted average shares, basic thousands of shares	—	—	444	68	155	—	5,155	1,027	1,026	—	3,859	4,022
Weighted average shares, diluted thousands of shares	—	—	444	68	155	—	5,155	1,027	1,026	—	3,859	4,022

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (DRMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,631	7,438	4,734	4,947	6,144	3,162	9,719	6,481	4,664	7,522	6,945	4,413
Inventory	—	—	—	—	—	—	—	—	—	—	93	150
Prepaid and other current assets	692	540	446	289	544	372	286	160	407	342	427	594
Total current assets	—	—	—	—	—	—	—	—	—	7,864	—	5,156
Property and equipment, net	—	—	—	—	—	—	—	—	—	—	—	129
Total assets	7,323	7,979	5,180	5,237	6,687	3,534	10,005	6,641	5,071	7,864	7,466	5,321
Accounts payable	474	866	823	1,327	864	808	1,395	414	453	461	318	1,120
Total liabilities	917	1,624	1,372	1,918	1,946	1,973	2,704	1,026	1,111	1,640	1,053	1,833
Accumulated deficit	(51,254)	(53,388)	(56,522)	(59,351)	(62,524)	(65,675)	(67,979)	(69,680)	(71,372)	(73,234)	(75,082)	(78,049)
Total stockholders' equity	6,407	6,355	3,808	3,318	4,741	1,561	7,301	5,614	3,960	6,223	6,413	3,488
Total liabilities and equity	7,323	7,979	5,180	5,237	6,687	3,534	10,005	6,641	5,071	7,864	7,466	5,321
Common shares outstanding (cover page) thousands of shares	3,189	6,661	6,661	1,316	2,041	5,431	6,378	682	1,026	4,022	4,022	4,022

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (DRMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,719)	(2,134)*	(3,134)	(2,829)	(3,173)	(3,151)*	(2,304)	(1,701)	(1,692)	(1,862)*	(1,848)	(2,967)
Stock-based compensation	131*	128*	587	20	21	30*	37	39	38	29*	43	42
Net cash from operating activities	(1,772)*	(1,147)*	(2,704)	(2,126)*	(3,419)*	(2,914)*	(1,934)	(2,690)*	(1,804)*	(1,329)*	(2,480)	(2,422)*
Proceeds from issuing common stock	(35)*	1,954*	0	2,410*	4,545*	(70)*	8,541	(548)*	(13)*	4,187*	—	—
Net cash from financing activities	(35)*	1,954*	0	2,339*	4,616*	(69)*	8,492	(548)*	(13)*	4,187*	1,903	(0)*
Net change in cash	—	—	(2,704)	213*	1,197*	(2,982)*	6,558	(3,238)*	(1,817)*	2,858*	(577)	(2,533)*

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Dermata Therapeutics	4,413	not reported	(2,422)*	4.0M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
MetaVia	12,634	not reported	(3,762)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.